Investor Relations

News Releases

Date Title and Summary Additional Formats
Toggle Summary Anika Appoints David Colleran as General Counsel
Seasoned executive brings extensive experience leading corporate legal and governance teams BEDFORD, Mass. --(BUSINESS WIRE)-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid
View HTML
Toggle Summary Anika Reports Fourth Quarter and Full Year 2019 Financial Results
Total Revenue Increases 10% Year-over-Year for the Fourth Quarter Completes Acquisitions of Parcus Medical and Arthrosurface Company Expects Total Revenue Growth in the 40% to 44% Range for Full Year 2020 BEDFORD, Mass. , Feb. 20, 2020 (GLOBE NEWSWIRE) --   Anika Therapeutics, Inc.
View HTML
Toggle Summary Anika Therapeutics Names Board Member Dr. Cheryl Blanchard as Interim CEO
BEDFORD, Mass. , Feb. 12, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that Dr. Cheryl Blanchard , a member of the Company’s Board of Directors since August 2018 , has been named interim Chief Executive Officer, effective immediately, while the Board continues
View HTML
Toggle Summary CORRECTING and REPLACING Anika to Issue Fourth-Quarter and Full-Year 2019 Financial Results and Business Highlights on Thursday, February 20
BEDFORD, Mass. --(BUSINESS WIRE)--Feb. 6, 2020-- First paragraph, first sentence should read: Anika Therapeutics, Inc. (NASDAQ: ANIK) today announced that the Company plans to issue its fourth-quarter and full-year 2019 financial results after the close of the market on Thursday, February 20, 2020
View HTML
Toggle Summary Anika Therapeutics Closes Acquisition of Arthrosurface
Transaction Accelerates Anika’s Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline BEDFORD, Mass. , Feb. 03, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.  (NASDAQ: ANIK), a global, integrated joint preservation
View HTML
Toggle Summary Anika Therapeutics Mourns the Sudden Passing of Joseph Darling, President and Chief Executive Officer
BEDFORD, Mass., Jan. 29, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ: ANIK) announced today with great sadness that Joseph Darling, its President and Chief Executive Officer, passed away unexpectedly on January 29, 2020 in Upstate New York. He was 62.
View HTML
Toggle Summary Anika Therapeutics Closes Acquisition of Parcus Medical
Transaction Accelerates Anika’s Revenue Growth, Broadens Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities and Expands Pipeline BEDFORD, Mass. , Jan. 24, 2020 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc.  (NASDAQ: ANIK), a global, integrated joint preservation
View HTML
Toggle Summary Anika Therapeutics to Acquire Parcus Medical and Arthrosurface
Accelerates Revenue Growth through Broadened Joint Preservation and Restoration Product Portfolio, Enhances Commercial Capabilities, and Expands Pipeline Conference Call & Webcast January 8 at 8:30 a.m. ET BEDFORD, Mass. --(BUSINESS WIRE)--Jan. 6, 2020-- Anika Therapeutics, Inc.
View HTML
Toggle Summary Anika Commences Full U.S. Commercial Launch of TACTOSET Bone Repair Therapy at Orthopaedic Summit 2019: Evolving Techniques
BEDFORD, Mass. --(BUSINESS WIRE)--Dec. 10, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform , today announced it will commence the full U.S.
View HTML
Toggle Summary Anika Therapeutics Announces Participation in MEDICA International Trade Fair and International Cartilage Regeneration and Joint Preservation Society Focus Meeting
BEDFORD, Mass. --(BUSINESS WIRE)--Nov. 15, 2019-- Anika Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid (HA) technology platform , today announced its participation in two upcoming
View HTML